Genetic Priority Score for Therapeutic Targets

The Icahn School of Medicine at Mount Sinai has developed a “genetic priority score” (GPS) to transform the prioritization process in drug development. Published in Nature Genetics, this novel tool amalgamates various types of human genetic data into a single, comprehensive score. This tool combines eight genetic features and drug indication information from the Open Targets and SIDER databases. It is designed to enhance the likelihood of success in clinical trials by focusing on genes with strong genetic support, thereby identifying established and potential novel drug targets.

This comprehensive analysis covered 19,365 protein-coding genes and 399 drug indications. Results are made accessible through a dedicated web portal. Researchers developed an advanced version of this tool incorporating the direction of genetic effects and drug mechanisms. The researchers plan to further refine the genetic priority score by incorporating additional genetic features and exploring more advanced algorithms.

This research is particularly significant in the pharmaceutical industry, where reducing clinical trial’s high costs and failure rates is a critical challenge. By streamlining the process of target prioritization, the genetic priority score offers a more efficient pathway in drug development. This research is a big step forward in personalized medicine and drug discovery, potentially impacting future therapeutic developments. This approach significantly advances prioritizing drug targets by leveraging genetic data.

Duffy, Áine, Ben Omega Petrazzini, David Stein, Joshua K. Park, Iain S. Forrest, Kyle Gibson, Ha My Vy, et al. 2024. “Development of a Human Genetics-Guided Priority Score for 19,365 Genes and 399 Drug Indications.” Nature Genetics, January, 1–9. https://doi.org/10.1038/s41588-023-01609-2

Originally published at https://medicalnewsobserver.com on January 4, 2024.

Drug Indications, Therapeutic targets